Clinical Trial Update: Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD [Phase 2]

View source ↗

Summary

A Phase 2 confirmatory dose-finding study comparing two doses of CHF 4226 pMDI (carmoterol) in patients with chronic obstructive pulmonary disease has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• CHF 4226 pMDI (Carmoterol) (carmoterol)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED